Clinical characteristics and frequency of TLR4 polymorphisms in Brazilian patients with ankylosing spondylitis  by Machado, Natalia Pereira et al.
r e v b r a s r e u m a t o l . 2 0 1 6;5 6(5):432–440
w ww.reumato logia .com.br
REVISTA BRASILEIRA DE
REUMATOLOGIA
Original article
Clinical  characteristics  and  frequency  of TLR4
polymorphisms in Brazilian  patients
with ankylosing  spondylitis
Natalia Pereira Machadoa, Eliana Nogueirab, Karen Osekia,
Pâmela Carolina Cruz Ebbinga, Clarice Silvia Taemi Origassab, Tatiane Mohovicb,
Niels  Olsen Saraiva Câmarab, Marcelo de Medeiros Pinheiroa,∗
a Divisão de Reumatologia, Departamento de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
b Divisão de Nefrologia, Departamento de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 10 February 2016
Accepted 1 May 2016
Available online 5 August 2016
Keywords:
Ankylosing spondylitis
TLR-4 polymorphisms
HLA-B27
a  b  s  t  r  a  c  t
Objectives: Innate immunity is involved in the physiopathology of ankylosing spondylitis
(AS),  with the participation of Gram-negative bacteria, modulation of human leukocyte
antigen (HLA) B27 and the involvement of pattern recognition receptors, such as Toll-like
receptors (TLRs). The aim of this study was to investigate the clinical characteristics and fre-
quency of TLR4 polymorphisms (Asp299Gly and Thr 399Ile) in a cohort of Brazilian patients
with  AS.
Methods: A cross-sectional study was carried out involving 200 patients with a diagnosis
of  AS and a healthy control group of 200 individuals. Disease activity, severity and func-
tional capacity were measured. The study of TLR4 polymorphisms was performed using the
restriction fragment length polymorphism method. HLA-B27 was analyzed by conventional
polymerase chain reaction. The IBM SPSS Statistics 20 program was used for the statistical
analysis, with p-values less than 0.05 considered signiﬁcant.
Results: Mean age and disease duration were 43.1 ± 12.7 and 16.6 ± 9.2 years, respectively.
The  sample was predominantly male (71%) and non-Caucasian (52%). A total of 66% of
the  group of patients were positive for HLA-B27. The sample of patients was characterized
by  moderate functional impairment and a high degree of disease activity. No signiﬁcant
association was found between the two TLR4 polymorphisms and susceptibility to AS.
Conclusions: TLR4 polymorphisms 399 and 299 were not more frequent in patients with AS
in  comparison to the health controls and none of the clinical variables were associated withthese  polymorphisms.
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Características  clínicas  e  frequência  de  polimorﬁsmos  em  TLR4
em  pacientes  brasileiros  com  espondilite  anquilosante
Palavras-chave:
Espondilite anquilosante
Polimorﬁsmos em TLR-4
HLA-B27
r  e  s  u  m  o
Objetivos: A imunidade inata está envolvida na ﬁsiopatologia da espondilite anquilosante
(EA), com a participac¸ão de bactérias gram-negativas, modulac¸ão do antígeno leucocitário
humano (HLA) B27 e o envolvimento de receptores de reconhecimento de padrões, como os
receptores Toll-like (TLR). O objetivo deste estudo foi investigar as características clínicas e a
frequência de polimorﬁsmos em TLR4 (Asp299Gly e Thr399Ile) em uma  coorte de pacientes
brasileiros com EA.
Métodos: Fez-se um estudo transversal que envolveu 200 pacientes com diagnóstico de
EA  e um grupo controle saudável de 200 indivíduos. Mediram-se a atividade da doenc¸a, a
gravidade e a capacidade funcional. O estudo dos polimorﬁsmos em TLR4 foi feito com o
método de polimorﬁsmo de fragmentos de restric¸ão. O HLA-B27 foi analisado por reac¸ão
em  cadeia da polimerase convencional. Usou-se o programa SPSS Statistics 20 da IBM para
a  análise estatística e foram considerados signiﬁcativos valores de p inferiores a 0,05.
Resultados: A média de idade e a durac¸ão da doenc¸a foram de 43,1 ± 12,7 e 16,6 ± 9,2 anos,
respectivamente. A amostra foi predominantemente do sexo masculino (71%) e de não bran-
cos (52%). Do grupo de pacientes 66% eram HLA-B27 positivos. A amostra de pacientes foi
caracterizada por uma alterac¸ão funcional moderada e um elevado grau de atividade da
doenc¸a.  Não foi encontrada associac¸ão estatisticamente signiﬁcativa entre os polimorﬁsmos
em  TLR4 e a susceptibilidade à EA.
Conclusões: Os polimorﬁsmos em TLR4 399 e 299 não foram mais frequentes em pacientes
com EA em comparac¸ão com controles saudáveis e nenhuma das variáveis clínicas esteve
associada a esses polimorﬁsmos.
© 2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma  licenc¸a CC
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attern-recognition receptors (PRRs) are a set of receptors
nvolved in recognition of pathogens in multicellular orga-
isms. Toll-like receptors (TLRs)1 function as PRRs and play
n essential role in the recognition of microbial components
nd endogenous ligands induced during the inﬂammatory
esponse.2–4
Among the gene polymorphisms of TLR, some of the most
idely studied are two co-segregated functional mutations in
he extracellular domain of human TLR4, which are located on
hromosome 4 and are associated with hyporesponsiveness
o bacterial lipopolysaccharides (LPS).5 Based on its evidence
f association with an increased risk of infection by Gram-
egative bacteria,5 such polymorphisms have been evaluated
n some inﬂammatory diseases in which the participation of
hese microorganisms has been implicated in the etiopathol-
gy, such as ankylosing spondylitis (AS).
Based on the premise of subclinical colitis in patients with
S and animal models that demonstrate the participation of
n infectious trigger by Gram-negative bacilli6,7 modulated by
he presentation of the antigen to HLAB27,8 the aim of the
resent study was to identify the frequency of TLR4 poly-
orphisms (Asp299Gly and Thr399IIe) in Brazilian patients
ith AS and investigate possible associations between these
olymorphisms and greater susceptibility to the disease as
ell as clinical and laboratory aspects of disease activity and
hronicity.BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The results of the association between TLR polymorphisms
and AS have been controversial in some clinical trials,9
probably because of different population studied. This fact
motivates investigation of this association in miscigenated
populations, like Brazilian one.
Materials  and  methods
Two hundred patients with a diagnosis of AS according to the
modiﬁed New York criteria10 or axial spondyloarthritis11 were
recruited from the spondyloarthritis clinic of the Rheumato-
logy Sector of the Federal University of Sao Paulo (Brazil) and
200 healthy individuals were selected from among volunteers
giving blood at the hospital of the same institution between
May 2011 and October 2013. All participants agreed to partici-
pate in the study by signing a statement of informed consent
(ethics committee number 1804/10).
Demographic and clinical data were collected and spe-
ciﬁc assessment tools were employed for the characterization
of disease activity and severity, such as the Bath Ankylos-
ing Spondylitis Disease Activity Index (BASDAI),12 Ankylosing
Spondylitis Disease Activity Score (ASDAS),13 Bath Ankylos-
ing Spondylitis Functional Index (BASFI),14 Bath Ankylosing
Spondylitis Metrology Index (BASMI)15 and modiﬁed Stoke
Ankylosing Spondylitis Spine Score (mSASSS).16The analysis of Asp299Gly and Thr399Ile polymorphisms
of TLR4 was performed using polymerase chain reaction
(PCR) followed by restriction enzyme digestion for each allele
 o l . 2434  r e v b r a s r e u m a t
(NCOI for 299 and HinfI for 399).17,18 GenomicDNA extraction
was performed using whole blood collected in ethylenedi-
aminetetraacetate (EDTA) using a DNA extraction kit (DNA
NucleoSpin®, Macherey-Nagel). The PCR ampliﬁcation was
performed with 50 ng of the DNA to be studied in a total vol-
ume of 20 L containing 0.8 L of potassium chloride 50 mM,
2 L of Tris (pH 8.4), 0.6 mM of magnesium chloride, 0.4 L
of each primer (10 nM), 0.4 L of deoxyribonucleotide mixture
(dATP, dCTP, dGTP and dTTP) and 0.06 L units of Taq platinum
DNA polymerase (0.015 U/L).The automatic thermal cycler (MJ  Research PTC-200) was
programmed for ampliﬁcation: initial denaturation (95 ◦C for
4 min), followed by 35 cycles of 95 ◦C for 45 s, 55 ◦C for 30 s and
72 ◦C for 1 min  30 s, with ﬁnal extension at 72 ◦C for 10 min. The
Table 1 – Clinical and demographic data of patients with ankylo
Clinical characteristics Patients
(n  = 200)
Age (years) 43.1 ± 12.7 
Male gender (n, %) 142 (71%) 
Caucasian ethnicity (n, %) 96 (48%)
Symptom duration (years) 16.6 ± 9.2
Time since diagnosis (years) 7.6 ± 6.2
Family history of AS (n, %) 46 (23%)
Presence of HLA-B27 (n, %) 130 (66%)
Peripheral involvement (n, %)
Arthritis (past or current) 99 (49.5%)
Enthesitis (past or current) 129 (64.5%)
Isolated axial involvement (n, %) 42  (21%)
Hip involvement (n, %) 26 (13%)
Anterior uveitis (past or current) (n, %) 74 (37%)
Current living habits (n, %)
Smoking 19 (9.5%)
Regular physical activity 44 (22%)
Speciﬁc disease indices
BASDAI 2.25 ± 2.02
BASMI 4.28 ± 2.30
BASFI 3.80 ± 2.52
ASDAS-Sed. rate 2.20 ± 1.06
ASDAS-CRP 2.07 ± 1.08
HAQ-S 1.05 ± 1.35
mSSASS 19.0 ± 22.32
Tests for inﬂammatory activity
Sed. rate (mm) 21.92 ± 20.47
CRP-us (mg/dL) 8.96 ± 13.53
Current conventional treatment (n, %)
NSAIDs 125 (62.5%)
Glucocorticoids 12 (6%)
Methotrexate 34 (17%)
Sulfasalazine 18 (9%)
TNF˛ inhibitors (n, %) 81 (40.5%)
Inﬂiximab 35 (17.5%)
Etanercept 24 (12%)
Adalimumab 22 (11%)
AS, ankylosing spondylitis; NSAID, non-steroidal anti-inﬂammatory drug;
Bath ankylosing spondylitis metrology index; BASFI, Bath ankylosing spond
score; HAQ-S, Health assessment questionnaire-Spondylitis; mSSASS, m
sedimentation rate; CRP-us, ultrasensitive C-reactive protein.
Mann–Whitney test. 0 1 6;5 6(5):432–440
forward and reverse primers were respectively 5′-GAT TAG CAT
ACT TAG ACT ACT ACC TCC ATG-3′ and 5′-GAT CAA CTT CTG
AAA AAG CAT TCC CAC-3′ for Asp299Gly and 5′-GGT TGC TGT
TCT CAA AGT GAT TTT GGG AGA A and 5′-CCT GAA GAC TGG
AGA GTG AGT TAA ATG CT-3′ for Thr399Ile. Electrophoresis in
2% agarose gel was performed to conﬁrm the DNA ampliﬁca-
tion.
An aliquot of 5 L with the appropriate restriction enzyme
was used for digestion of the PCR product at 37 ◦C for 2 h. Elec-
trophoresis was performed in 4% agarose gel (Agarose 1000
Invitrogen, Eugene, OR, USA) for identiﬁcation of the TLR4
alleles. The gel was stained with Sybr Gold (Nucleic acid gel
stain, Invitrogen, Eugene, OR, USA) and visualized using the
Storm 849 system (Molecular Dynamics, USA).
sing spondylitis and healthy controls.
Controls
(n  = 200)
p
38.5 ± 11.2 0.001
121 (60.5%) 0.027
 BASDAI, Bath ankylosing spondylitis disease activity index; BASMI,
ylitis function index; ASDAS, Ankylosing spondylitis disease activity
odiﬁed Stokes ankylosing spondylitis spine score; Sed. rate, blood
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Table 2 – Frequency of TLR4 polymorphisms (299 and
399) in patients and controls.
TLR-4 polymorphisms Patients
n = 200
Controls
n  = 200
p
Asp299Gly
Wild 182 (91%) 178 (89%) 0.505
Heterozygote 17 (8.5%) 22 (11%)
Homozygote 1 (0.5%) 0
Thr399IIe
Wild 187 (93.5%) 186 (93%) 0.50
Heterozygote 13 (6.5%) 14 (7%)
Homozygote 0 0r e v b r a s r e u m a t o l
The analysis of HLA-B27 was performed using conventional
CR in an automatic thermal cycler (MJ  Research PTC-200):
0 ng of DNA from each sample, 0.9 mol/L of each forward and
everse primer, 1.1 mmol/L of magnesium chloride, 200 mol/L
f deoxyribonucleotide mixture (dATP, dCTP, dGTP and dTTP)
nd 2 U of Taq DNA polymerase for a total volume of 25 L. The
orward and reverse primers for the reaction were respectively
91S (5′-GGG TCT CAC ACC CTC CAG AAT-3′) and 136AS (5′-CGG
GG TCC AGG AGC T-3′). The cycling conditions were 100 s at
4 ◦C, followed by 30 cycles of 1 min  at 94 ◦C, 1 min  at 64 ◦C
nd 2 min  at 72 ◦C, with ﬁnal extension at 72 ◦C for 10 min  in
0 consecutive cycles.
To evaluate the reaction quality (internal control), reactions
ere performed using primers for -globin for all samples
nder the same conditions used for the HLA-B27 reactions.
he primers for these reactions were PCO4 (5′-CAA CTT CAT
CA CGT TCA CC-3′) and GH20 (5′-GAA GAG CCA AGG ACA GGT
C-3′). The PCR products were analyzed through electrophore-
is in 1% agarose gel run for one hour at 100 V.
Numerical data were expressed as mean and standard
eviation. The Kolmogorov–Smirnov test was used to deter-
ine the distribution of the data (normal or non-normal).
ither the Mann–Whitney test or Kruskal–Wallis test was used
or comparisons among the categorical and numerical data.
he chi-square test was used to determine the distribution of
he TLR4 polymorphisms between groups as well as for the
omparison of the categorical variables. Spearman’s correla-
ion coefﬁcients were calculated to determine the strength
f correlations among the continuous variables. Bivariate and
ultivariate logistic regression models were constructed with
ariables that exhibited signiﬁcant associations in the pre-
ious tests. The IBM SPSS 20 program was used for the
tatistical analysis, with p-values less than 0.05 considered
igniﬁcant.
esults
able 1 displays the clinical and demographic data of the
00 patients. As expected, the male gender was predomi-
ant. Approximately one quarter of the patients had a family
istory of AS and half the sample reported current or past
eripheral involvement. Nearly 40% of the patients had ante-
ior uveitis. The prevalence rates of current smoking and the
egular practice of physical exercise were low.
Mean disease activity was high, with signiﬁcant functional
nd mobility impairment reﬂecting the long duration of the
isease. More  than 60% of the patients made regular use of
 non-steroidal anti-inﬂammatory drug and 35% used a syn-
hetic disease-modifying anti-rheumatic drug. Nearly half the
atients used TNF inhibitors, with equal distribution among
tanercept, inﬂiximab and adalimumab.
The study of HLA-B27 was performed on 197 (98.5%)
atients with AS and 60 (30%) healthy individuals, 66% (n = 130)
nd 1.6% (n = 1) of whom tested positive, respectively. Extra-
rticular manifestations were found in 80 patients (40%), the
ost frequent of which was acute anterior uveitis (n = 74; 37%),
ollowed by circinate balanitis (n = 3; 1.5%), nonspeciﬁc colitis
n = 2; 1%) and sterile urethritis (n = 1; 0.5%).Chi-square test.
No statistically signiﬁcant differences between the patients
and healthy controls were found regarding Asp299Gly and
Thr399Ile polymorphisms. Due to the very low number of
homozygotes, heterozygous and homozygous patients were
included in the same group for the tests. The 299 and
399 polymorphisms were in Hardy–Weinberg (HW) equilib-
rium in the patients (HW-2 = 0.73, p = 0.39 and HW-2 = 0.22,
p = 0.63, respectively) and controls (HW-2 = 0.68, p = 0.41 and
HW-2 = 0.26, p = 0.61, respectively), demonstrating the conser-
vation of genotype frequencies across generations (Table 2). A
tendency was found toward a greater frequency of non-co-
segregation of the alleles in the control group in comparison
to the patients with AS (Table 3).
For a more  detailed analysis, the patients were sepa-
rated into subgroups based on clinical characteristics. Female
patients had a higher body mass index (BMI) as well as higher
HAQ-S and ASDAS-Sed. rate scores. Females also had shorter
disease duration, lesser severity of sacroiliac involvement as
well as lower mSASSS and BASMI scores in comparison to
males (Table 3). After controlling for confounding variables
in the logistic regression model, only BMI  (p = 0.014) and the
BASMI score (p = 0.02) remained signiﬁcantly associated with
gender.
In the logistic regression analysis using positivity for B27 as
the dependent variable, signiﬁcant associations were found
for peripheral arthritis (p = 0.039), uveitis (p = 0.033) and the
use of TNF inhibitors (p = 0.003) (Table 4). Among the patients
positive for HLA-B27, a tendency was found toward a predom-
inance of Caucasians (p = 0.058). Moreover, greater prevalence
rates were found in this group regarding anterior uveitis, more
severe sacroiliac involvement (Grade IV), longer disease dura-
tion and a greater frequency of biological agents (p < 0.05)
(Table 5).
Patients with the adult form of the disease had higher
scores on the BASFI, BASDAI and HAQ-S, were older and had
longer disease duration. Those with the juvenile form of the
disease more  frequent reports of a family history of AS, made
more use of sulfasalazine and reported more  side effects from
TNF inhibitors. However, none of these variables remained
statistically signiﬁcant in the ﬁnal multiple regression
model.Non-Caucasian patients had a higher BMI  and BASMI score
in comparison to Caucasian patients (Table 6). However, only
the BASMI score remained signiﬁcant in the logistic regression
436  r e v b r a s r e u m a t o l . 2 0 1 6;5 6(5):432–440
Table 3 – Characteristics of patients with ankylosing
spondylities according to gender.
Variables Male
(n = 142)
Female
(n  = 58)
p
Ethnicity
Caucasian 67 (47.2%) 29 (50%)
Non-Caucasian 75 (52.8%) 29 (50%) 0.717
Onset
Adult 118 (83.1%) 50 (86.2%)
Juvenile 24 (16.9%) 8 (13.8%) 0.586
HLA-B27+ 96 (67.6%) 34 (58.6%) 0.158
Arthritis 68 (47.9%) 31 (53.4%) 0.475
Entesitis 93 (65.5%) 36 (62%) 0.646
Anterior uveitis 53 (37.3%) 21 (36.2%) 0.882
Family history of
AS
36 (25.3%) 10 (17.2%) 0.216
Pure axial
involvement
29 (20.4%) 13 (22.4%) 0.754
BMI (kg/m2) 24.81 ± 3.72 25.80 ± 3.87 0.02
BASMI 4.63 ± 2.22 3.43 ± 2.27 0.001
mSASSS 22.54 ± 23.34 10.64 ± 17.2 <0.0001
ASDAS-Sed. rate 2.11 ± 1.05 2.42 ± 1.04 0.036
HAQ-S 1.03 ± 0.61 1.11 ± 2.33 0.03
Sed. rate (mm) 19.3 ± 19.6 28.35 ± 21.31 0.001
Disease duration
(years)
17.5  ± 9.43 14.43 ± 8.5 0.02
Radiographic sacroilitis
II 11 (7.7%) 4 (7.0%) 0.044
III 66 (46.5%) 38 (65.5%)
IV 65 (44.0%) 16 (27.6%)
AS, ankylosing spondylitis; BMI, body mass index; BASMI,
Bath ankylosing spondylitis metrology index; ASDAS, Ankylos-
ing spondylitis disease activity score; HAQ-S, Health assessment
questionnaire-Spondylitis; mSASSS, modiﬁed Stokes ankylosing
spondylitis spine score; Sed. rate, blood sedimentation rate; chi-
square and Mann–Whitney tests.
Table 4 – Characteristics of patients with ankylosing
spondylitis according to positivity for HLA-B27.
Variables HLA-B27
positive
(n = 130)
HLA-B27
negative
(n  = 67)
p
Ethnicity
Caucasian 69 (53.1%) 26 (39%) 0.058
Non-Caucasian 61 (46.9%) 41 (61.2%)
Onset
Adult 103 (82.4%) 55 (87.3%) 0.386
Juvenile 22 (17.6%) 8 (12.7%)
Arthritis 58 (44.6%) 40 (59.7%) 0.045
Enthesite 85 (65.4%) 43 (64.2%) 0.867
Uveitis 56 (43.1%) 17 (25.4%) 0.015
Family history of AS 31 (23.8%) 14 (20.9%) 0.640
Radiographic sacroiliitis
II 9 (6.9%) 6 (8.9%)
III 59 (45.4%) 44 (65.7%)
IV 62 (47.7%) 17 (25.4%) 0.01
Pure axial
involvement
28  (21.5%) 12 (17.9%) 0.549
Disease duration
(years)
8.28  ± 6.57 6.39 ± 5.07 0.039
TNF  ˛ inhibitors 59 (45.4%) 16 (23.9%) 0.003
Chi-square and Mann–Whitney tests.
adjustments.
When the patients were classiﬁed by remission (<1.3), mod-
erate (≥1.3 and <2.1), high (≥2.1 and <3.5) or very high (≥3.5)
Table 5 – Characteristics of patients with ankylosing
spondylitis according to ethnicity.
Variables Caucasian
(n = 96)
Non-
Caucasian
(n  = 104)
p
Onset
Adult 78 (81.3%) 90 (86.5%)
Juvenile 18 (18.7%) 14 (13.5%) 0.308
Arthritis 47 (49%) 52 (0.5%) 0.883
Enthesitis 61 (63.5%) 68 (65.4%) 0.786
Uveitis 34 (35.4%) 40 (38.5%) 0.656
Family history of AS 23 (24%) 23 (22.1%) 0.757
Radiographic sacroilitis
II 6 (6.2%) 9 (8.6%)
III 59 (61.4%) 45 (43.3%)
IV 31 (32.3%) 50 (48.1%) 0.037
Pure axial
involvement
21  (21.8%) 21 (20.2%) 0.770
BMI (kg/m2) 24.81 ± 3.72 25.8 ± 3.87 0.048
BASMI 3.89 ± 2.18 4.65 ± 2.36 0.023
AS, ankylosing spondylitis; BMI, body mass index; BASMI, BathThe p value in bold means statistically signiﬁcant.
analysis (p = 0.004). The most frequent degree of radiographic
sacroiliitis was Grade III (n = 103; 51.8%), followed by Grades IV
(40.5%) and II (7.5%).
Among the patients on TNF inhibitors, 20 (24.7%) needed
to change agents: ﬁve (6.2%) due to primary failure (6.2%), six
(7.4%) due to secondary failure and 13 (16%) due to adverse
events, especially infusion reactions and infection. Moreover,
four (2%) of these patients changed TNF inhibitors for more
than two agents.
Anterior uveitis was associated with longer disease dura-
tion (p = 0.002), but lost its statistical signiﬁcance in the ﬁnal
model. Hip involvement was associated with chronicity and
lower disease activity scores (data not shown). In the ﬁnal
logistic regression model, longer disease duration (p = 0.039),
a higher BASFI score (p = 0.027) and a lower BASDAI score
(p = 0.024) remained statistically signiﬁcant.
Patients with longer disease duration had higher mSASSS
and BASMI scores as well as a lower ASDAS-Sed. rate score.
In the ﬁnal model, only ASDAS-ESH (p = 0.015) remained
signiﬁcant. Longer symptom duration was correlated with
higher BASMI, BASFI, HAQ-S and mSSASS scores as well as
a lower BASDAI score. In the ﬁnal model, BASMI (p < 0.0001)AS, ankylosing spondylitis.
The p value in bold means statistically signiﬁcant.
and BASDAI (p = 0.016) remained signiﬁcant after the multipleankylosing spondylitis metrology index.
Chi-square and Mann–Whitney tests.
The p value in bold means statistically signiﬁcant.
r e v b r a s r e u m a t o l . 2 0 1
Table 6 – Characteristics of patients with ankylosing
spondylitis according to hip involvement.
Variables Hip involvement p
Yes (n = 26) No (n = 174)
Age (years) 47.7 ± 11.3 42.4 ± 12.7 0.035
Time since
diagnosis
(years)
10.3 ± 7.9 7.2 ± 5.9 0.04
Disease duration
(years)
23.4 ± 9.6 15.6 ± 8.8 <0.0001
BASDAI 1.20 ± 1.43 2.42 ± 2.06 0.001
BASMI 5.55 ± 1.52 4.10 ± 2.33 0.002
BASFI 5.03 ± 2.52 3.61 ± 2.48 0.011
mSASSS 27.33 ± 24.46 17.77 ± 21.80 0.035
ASDAS-CRP 1.55 ± 0.88 2.14 ± 1.09 0.009
HAQ-S 1.86 ± 3.72 0.93 ± 0.61 0.017
BASDAI, Bath ankylosing spondylitis disease activity index; BASMI,
Bath ankylosing spondylitis metrology index; BASFI, Bath anky-
losing spondylitis function index; ASDAS, Ankylosing spondylitis
disease activity score; mSASSS, modiﬁed Stokes ankylosing
spondylitis spine score.
d
q
a
A
a
e
c
S
(
D
T
B
b
a
i
n
r
s
t
i
t
g
f
p
i
n
v
i
p
m
sChi-square and Mann–Whitney tests.
The p value in bold means statistically signiﬁcant.
isease activity based on the ASDAS score, the following fre-
uencies were found: 14% (n = 28), 31.5% (n = 63), 37% (n = 74)
nd 17.5% (n = 35), respectively.
The BASDAI score was positively correlated with BASFI,
SDAS-Sed. rate, ASDAS-CRP, Sed. rate, CRP and HAQ-S
nd negatively correlated with mSSASS. Following the lin-
ar multivariate regression, BASDAI remained signiﬁcantly
orrelated with BASFI (p = 0.001), HAQ-S (p = 0.047), ASDAS-
ed. rate, ASDAS-CRP and Sed. rate (p < 0.0001), but not CRP
p = 0.247).
iscussion
LR4 polymorphisms 399 and 299 were not more  frequent in
razilian patients with AS in comparison to the health controls
ecause there were no statistical differences between patient
nd control groups. The inﬂuence of TLR4 polymorphisms
n the etiopathogenesis of infections, especially by Gram-
egative bacteria, is well known,19 as such polymorphisms
esult in a phenotype that is little responsive to endotoxins
temming from the infectious process that cause aberrant
ransduction of the signal in the presence of microorgan-
sms. However, a number of authors have recently questioned
he inﬂuence of polymorphisms of this receptor on the pro-
ression, severity and outcome of infections, suggesting that
actors related to the host are more  important than polymor-
hisms per se.20,21
Bacterial or intracellular components can initiate the
nﬂammatory process and trigger sensitization to an endoge-
ous antigen through molecular mimicry, persistently acti-
ating adaptive innate immunity and perpetuating the
nﬂammatory process. The trigger may not necessarily be
athogenic, but rather makes of part of the normal resident
icrobiota and can culminate in the development of diseases,
uch as AS, in genetically susceptible individuals.2 6;5 6(5):432–440 437
There is some evidence of an association between TLR poly-
morphisms (299 and 399) and AS,6,22,23 but this association
has not been conﬁrmed in other studies.24–26 The same is
true for Asp896Gly.27 The S180L polymorphism of an adap-
tor protein of TLR2 and 4 (TIRAP), which has demonstrated
to play a protective role against the occurrence of systemic
lupus erythematosus, has also demonstrated no association
with AS.28
Kyo et al. found that mutant mice (C3H/Hej) for TLR4 did
not develop arthritis after the intra-joint injection of LPS from
E. coli, unlike the wild group.29 This has raised the hypothesis
that the mutation in TLR4 may diminish the intensity of the
innate immune response, playing a protective role rather than
promoting autoimmunity.
The present data show that the 299 and 399 polymorphisms
of TLR4 are not genetic factors of greater susceptibility to AS,
which is in agreement with a recent meta-analysis involving
data compiled from nine studies on this topic.30 Moreover,
it is important to point out that one of the largest genetic
studies (The Australo-Anglo-American Spondyloarthritis Con-
sortium), involving more  than two thousand patients of
European descent with AS, also found no association between
TLRs and susceptibility to the disease.9 According to the
authors cited, the main associations occurred with two  desert
genes (2p15 and 21q22) as well as with IL-23R, IL-1R2, ANTXR2
and ERAP-1.
The expression of TLR4 is related to the interface between
the immune system and the environment as well as acute
and chronic inﬂammatory responses in patients with AS,31–33
but polymorphisms doesn’t seem to be associated with a
greater risk of developing the disease.30 Population-based
studies involving healthy individuals indicate heterogene-
ity in the geographic distribution of these polymorphisms.
The frequency ranges from 4 to 10% in Caucasians34 in the
present cohort, while a frequency of 16% is reported among
Africans.35 There are no reports of this polymorphism in
Asians.25
Considering that Brazilian population is highly mixed with
multiple ethnic groups, we cannot assure similar results if
patients from other parts of the country, particularly no Euro-
pean background, had been included.
One cannot discard the possibility of a weak association
that may be representative in a larger sample size than that
employed in the present study. However, a study carried out in
the United Kingdom involving more  than 500 patients with AS
also found no association.6 The same has been true for other
ethnicities, such as Hungarian, Finnish, Korean, Canadian and
Dutch populations. Another point to consider is the low preva-
lence of homozygous genotypes for the TLR4 polymorphisms
in the present cohort, which is similar to ﬁndings described in
other populations.
It has been demonstrated that transgenic rats for HLA-B27
do not develop inﬂammation of the entheses or intestines,
although these animals develop genital and skin lesions under
sterile conditions, demonstrating the role of infectious agents
as an inﬂammatory trigger.36 Moreover, the participation of
the environment is a determinant in the emergence of the
disease, as only two to ﬁve percent of the population positive
for HLA-B27 develops AS. Based on this fact, the interaction
between HLA-B27 and TLR4 polymorphisms was investigated
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in the present sample, but was not demonstrated, as no signif-
icant differences in the polymorphisms were found between
the patients and healthy controls. Moreover, the number of
patients with polymorphisms was relatively small.
Regarding clinical aspects, males exhibited more  severe
axial radiographic damage and longer disease duration than
females, which is similar to ﬁndings reported in another
Brazilian cohort37 as well as in other populations, although
with no signiﬁcant gender difference regarding peripheral
involvement.38 However, these ﬁndings should be interpreted
with caution, since the only signiﬁcant differences after con-
trolling for confounding variables, especially disease duration
and age, were BASMI score, which was higher among males,
and BMI, which was higher among females.
Miscegenation likely contributed to the two peculiarities
found in the present sample. The ﬁrst was the lesser fre-
quency of positivity for HLA-B27 (66%) in comparison to
another Brazilian cohort (78.2%)37 and studies involving Cau-
casian populations (more than 90%).39 Fifty-two percent of
the present cohort was non-Caucasian, which better reﬂects
the Brazilian population in comparison to previous studies
(75.5% Caucasian patients).37 The second peculiarity was the
greater peripheral or mixed involvement, which has also been
reported in other mixed-race populations.39,40 Among only
the Caucasian patients in the present study, the frequency of
positivity for HLA-B27 was 75%, which is very close to the fre-
quency reported in a previous Brazilian cohort39 as well as that
reported in a recent French study.41
The patients with high chronicity index scores generally
had lower disease activity index scores, such as the associ-
ation between hip involvement and both a worse BASFI and
lower BASDAI score. Likewise, disease duration was correlated
with a lower BASDAI and higher BASMI score. Interestingly, the
BASDAI score was correlated with the other activity markers
(ASDAS-Sed. rate and CRP) as well as worse functionality, but
the correlation with CRP, which is one of the most standard-
ized parameters for studying inﬂammatory activity in patients
with AS,42 was non-signiﬁcant.
As expected, the presence of HLA-B27 was signiﬁcantly
associated with extra-articular manifestations (uveitis)43 and
lesser peripheral involvement, but no associations were found
with the radiographic score or any speciﬁc AS assessment tool,
including activity, function and mobility. This ﬁnding reﬂects
the more  recent knowledge that this genetic aspect is not an
associated factor of a poorer prognosis regarding the forma-
tion of new bone.44
The prevalence of the juvenile form (16%) was similar
to that found in Caucasians (8.6–21%) Turks (13.4%) and
other Brazilian cohort (16%)45 as well as lower than the
rates reported for Mexicans (28–54%) and Koreans (41.3%).46
The inclusion of these patients did not exert an important
impact on the clinical, laboratory and imaging outcomes
analyzed, which is in agreement with the notion that this
subgroup is part of the same spectrum of the disease. In
contrast, some authors report lesser axial involvement and
a greater proportion of peripheral involvement, especially the
knees, in comparison to onset of the disease after the age of
16 years.37,45,46
The present study has limitations that should be
addressed, such as the sample size for studies on gene
1 0 1 6;5 6(5):432–440
polymorphisms and the higher proportion of Caucasian indi-
viduals in this cohort, what may not reﬂect Brazilian AS
population. Our data suggest that these TLR4 variations are
unlikely to play a role in the etiopathogenesis of AS. This ﬁnd-
ing, however, does not exclude the possibility that functional
abnormalities of the TLRs or other molecules closely associ-
ated with the TLRs signaling are important in the pathogenesis
of spondylarthropathies.
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